Drug Research
BMS, Dragonfly Enter Exclusive License for Sixth TriNKET Immunotherapy Candidate
Bristol Myers Squibb has exercised its option under a research collaboration with Dragonfly Therapeutics, Inc, to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, bringing the total drug candidates licensed by BMS to seven including...
News
Sarepta and Catalent Expand Strategic Manufacturing Partnership with Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Catalent and Sarepta Therapeutics have signed a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD). The agreement also structures how Catalent may support...
Drug Research
FUJIFILM Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies
FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular...
Drug Research
Aurisco to Build Oligonucleotides Manufacturing Facility in China
Aurisco, a pharmaceutical company and contract development and manufacturing organization (CDMO) in China, is cooperating with global life sciences company Cytiva, to build its first Oligo FlexFactory platform for commercial production.
The Oligo FlexFactory platform is the first of the...
Drug Research
Sartorius, RoosterBio Partner to Advance the Manufacture of Exosomes
Sartorius has extended a strategic collaboration agreement with RoosterBio Inc. to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. The companies will provide solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based...
Drug Research
GHO Capital and The Vistria Group Complete Acquisition of Leading CDMO Alcami Corporation
Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), and The Vistria Group today announced that they have completed the acquisition of Alcami Corporation ("Alcami"), a leading pharmaceutical contract development and manufacturing organization (CDMO), from funds affiliated with Madison...
Drug Research
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
Duality Biologics, a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers and autoimmune diseases, announced a license agreement with Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read